Review of NICE Technology Appraisal Guidance No.64; Human growth hormone (somatropin) in adults with growth hormone deficiency

Proposal to move the existing guidance to the static list

The planned date for review of the above guidance was scheduled to be ‘within 6 months’ of the publication of expected trial data.  In December 2013, the Institute was notified that this trial had closed. 

Consequently, the Institute has now decided to consider this topic for review, to assess whether any other sufficient new evidence has emerged for the Appraisal Committee to be asked to undertake a full review appraisal.

No new evidence has been found that would lead to a change in the existing recommendations.  As a result, we propose that TA64 should move to the static list of technology appraisals.

Topics on the static list may be transferred back to the active list for further appraisal if new evidence becomes available that is likely to have a material effect on the last guidance issued.

In order to be completely confident that this is appropriate, we are asking all relevant consultees and commentators, to inform us of any evidence which will help us decide the best way to update this guidance.  Please see appendix A for a full list of the organisations we have contacted.